Stay updated with breaking news from Benedict Cross. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New drug discovery platform integrates computational approaches with molecular biology for development of novel degrader therapeutics PhoreMost Ltd., a leading UK biopharmaceutical company unlocking
The partnership combines systems in order to identify subtle phenotypic changes in living cells - News - PharmaTimes
/PRNewswire/ -- PhoreMost Ltd. and ThinkCyte K.K. today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using...
What if there was a way to avoid many of the early drug discovery pitfalls? In this GEN webinar, our distinguished speaker Dr. Benedict Cross, CTO of PhoreMost, will tell us about a newly developed screening approach called PROTEINi that “pre-discovers” the identity of new phenotypically tractable targets and their mechanisms for drug development.